OncoSec Medical announced that it has entered into a research collaboration agreement with the University of California, Los Angeles, or UCLA, on behalf of Roger Lo and his research team. Under the research collaboration, Lo and his research team will perform genetic, transcriptomic and methylomic analyses of patients in OncoSec’s PISCES/KEYNOTE-695 Phase 2b clinical trial, which is evaluating TAVO in combination with KEYTRUDA, or pembrolizumab, for the treatment of metastatic melanoma in patients that have progress after receiving all available treatments including anti PD-L1 checkpoint immunotherapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.